Bot/Bal in MSS CRC: Efficacy in Non-Liver Metastatic Sites

By Benjamin L. Schlechter, MD - Last Updated: March 19, 2025

Benjamin L. Schlechter, MD, discusses the unique mechanisms of action of botensilimab, and how this therapy is well-suited to treat microsatellite stable colorectal cancer, particularly in non-liver metastatic sites.

Dr. Schlechter also highlights how the implications of this research may affect long-term efficacy and durability of response in patients with MSS CRC.

Find more ASCO 2024 coverage here.

From Tumor Sidedness to Team Science: Dr. Alan Venook Reflects on a Career That Changed Colorectal Cancer Care

Alan P. Venook, MDColorectal Cancer | May 8, 2025

Dr. Alan Venook reflects on how his leadership roles have shaped his collaborative approach to cancer research and treatment.

Sotorasib Plus Panitumumab Prolongs Progression-Free Survival in Patients With Chemorefactory KRAS G12C mCRC

Jessica GangaColorectal Cancer | May 6, 2025

Sotorasib plus panitumumab may prolong progression-free survival in patients with KRAS G12C mCRC.

Early Onset Colorectal Cancer: Trends, Epidemiology, and Screening

Jessica Nye, PhDColorectal Cancer | May 5, 2025

Experts speak on the new face of CRC, the potential mechanisms for these trends, and how CRC screening programs should react.

5-Year Outcomes of DYNAMIC: ctDNA-Guided Adjuvant Therapy in Colon Cancer

Jeanne Tie, MD, MBChBColorectal Cancer | May 1, 2025

Dr. Tie discusses the beneficial results seen with a ctDNA-guided approach, and touches on its role in future trials.

HER2-Directed Therapies in Colorectal Cancer: Progress and Challenges

James Cleary, MD, PhDColorectal Cancer | April 17, 2025

Dr. James Cleary discusses the use of HER2-directed therapies for the treatment of CRC.

Bot/Bal in MSS CRC: Efficacy in Non-Liver Metastatic Sites

Related Posts